Immunodiagnostic Systems Share Discussion Threads

[philo124] 28/6/2011 18:23

Pretty High volume today.

[philo124] 28/6/2011 14:38

Have seen Brewin Note. Price target upped to 1230p from 1195p, Conviction Buy.

[philo124] 28/6/2011 07:54

Rodozz,my decision was a decision, not an idea.

[rodozz] 28/6/2011 00:03

Philo124 hope your decision to sell FPM and buy XEL is sitting well with you.

Next time maybe keep your ideas to yourself ?

[philo124] 27/6/2011 22:42

Thanks; in ODX as well.

[campbed] 27/6/2011 22:40

Agree with Phil -- this company look to have many things going for it -- attacive market place, high margins, competent board etc

[philo124] 27/6/2011 22:36

Great Results!

[spacecake] 04/6/2011 19:19

£12, short term target for this month run up to the results ?

[philo124] 01/6/2011 10:54

Nearly at £10; my target £12. fwiw.

[philo124] 05/5/2011 19:10

GOOD rise today.

[rumithepoet] 13/4/2011 15:31

Market maven Ben Jaglom on Immunodiagnostic

[dasv] 06/4/2011 08:26

good update imo. I sold out around the japan crisis. This will make me re-think

Immunodiagnostic Systems Holdings plc

Trading Update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of specialist diagnostic testing kits for the clinical and research markets, provides a trading update for the financial year ending 31 March 2011.

Turnover for the year ending 31 March 2011 is expected to be £50.1m, circa 35% ahead of last year's performance (FY10: £37.2m) with trading in all of the Company's main territories having increased year on year. Sales of both manual vitamin D and automated products have increased compared to last year.

Revenues from our manual Vitamin D kits increased by 27% to £27.9m compared to same period last year (FY10: £22m).

We are also pleased to report that sales and placements of the IDS-iSYS system have continued to increase and in the second half of the year, as we have sold and or placed another 101 instruments bringing the total number post launch to 241.

Number of IDS-iSYS instruments sold and placed post launch:

Accounting Period
Reagent Rentals
Distribution Sales
OEM & Partners
Total

cumulative
cumulative
cumulative
cumulative
Comparative H1
12
5
10
27
Comparative H2
31
19
24
74
Current year H1
62
28
50
140
Current year H2
113
46
82
241

Average revenue per instrument from our own reagent rental accounts was ahead of management expectations at £102,000, circa 32% ahead of last year's performance (FY10: £77,000).

IDS-iSYS revenues accounted for circa 21% of total turnover, with sales in H2 of £7.0m compared to £3.3m in H1. Comparative sales in the previous year were H2: £2.1m and H1 £0.6m.

During the period the Company signed an exclusive Agreement with Omega Diagnostics Group PLC giving them the exclusive rights to develop and distribute their range of allergy products on the IDS-iSYS. In return IDS receives a licence fee, a royalty on Omega automated product sales and revenues from both instrument and consumable sales.

Balance Sheet

The Company has been asked to consider a renegotiation of the timing of payment of the deferred consideration receivable (€3.4m) in respect of the disposal in December 2008 of its Haematology Division. As of today's date there has been no provision made against this amount in the Company's Accounts. The position is being reviewed by the Board in light of this request.

Outlook

We look forward to reporting our results for the financial year ended 31 March 2011 on Monday 27 June 2011 and continue to look forward to the current year with confidence.

[philo124] 06/4/2011 08:04

With Mkt Cap of 240m and Profit growth i don't think it's material and neither
should the market.

[alter ego] 06/4/2011 07:52

How do you think the market will react to the news that deferred consideration payment may not be forthcoming?

[philo124] 06/4/2011 07:42

Great! I am going for historic 48p eps, up 60% on last year. Previously set a price target of £12.

[alter ego] 06/4/2011 07:32

trading update
www.investegate.co.uk/Article.aspx?id=201104060700053626E

[philo124] 31/3/2011 07:49

Useful RNS.

[silverfern] 28/3/2011 08:48

David Evans is non exec Chairman of Omega

[philo124] 12/3/2011 18:31

There was 150,000 sell at 730p friday am.

[spacecake] 11/3/2011 13:48

Seems to have no buying interest, directors selling, no news flow.

[jpcarvil] 11/3/2011 12:42

this looks bad, no news? any ideas anyone?

[philo124] 24/2/2011 14:46

Great, thanks a lot! My target £12 Also GB Group 48p target which i hold so that was useful to know too!

[nellie1973] 24/2/2011 14:35

Broker upgrade

[philo124] 23/2/2011 12:28

Chunky trades again. Looked at historic RNS's- not due for any more until mid April.

[philo124] 06/2/2011 08:59

I still maintain my £12 target despite all the rumours that have been flying around in the last 6 weeks.